Tempus AI Inc. reported strong financial results for the second quarter of 2025, with revenue reaching $314.6 million, an 89.6% increase year-over-year, surpassing analyst estimates of approximately $297 million. The company posted an adjusted loss per share of $0.22, better than the expected $0.24 loss, and an adjusted EBITDA loss of $5.6 million, showing improvement from prior periods. Gross profit rose 158.3% to $195 million, driven by a 115.3% surge in genomics revenue to $241.8 million and a 36% increase in data and services revenue to $72.8 million. Net loss narrowed significantly to $42.8 million from $552.2 million in the prior year. Tempus AI performed 212,000 next-generation sequencing tests during the quarter and reported a cash balance of $293 million, up $70 million quarter-over-quarter. The company also issued $750 million in 0.75% convertible notes. Following the strong quarter, Tempus AI raised its full-year 2025 revenue guidance to approximately $1.26 billion, up from $1.25 billion, representing an 82% increase year-over-year, and now expects positive adjusted EBITDA of $5 million. The CEO highlighted faster-than-expected growth and improved margins, citing a 30% increase in clinical volumes for the quarter. These results and outlook enhancements contributed to a notable rise in Tempus AI’s stock price and positive analyst sentiment.